PATH and partners are developing iOWH032 as a complement to oral rehydration solution for diarrheal disease treatment. Acting via inhibition of the cystic fibrosis transmembrane conductance regulator chloride channel, iOWH032 is a novel, low-molecular-weight compound intended to reduce fluid and electrolyte loss in cases of cholera toxin-induced secretory diarrhea.

Publication date: August 2017

Region: Global

As part of the Tribendimidine (TrBD) Consortium, PATH and partners are advancing TrBD—an anthelmintic drug with demonstrated excellent efficacy against soil-transmitted helminth (STH) infections—as an additional drug option for control and treatment of STH. Integration of TrBD into global mass drug administration campaigns could accelerate progress to eliminate STH in endemic regions.

Publication date: August 2017

Region: Global

The Drug Development program represents a key innovation platform at PATH. Guided by a passion for health equity, we work with public- and private-sector stakeholders to develop and advance medicines for diseases disproportionately affecting women and children in low-resource settings. Areas of focus include enteric and diarrheal diseases, neglected tropical diseases, and maternal and child health.

Publication date: August 2017

Region: Global

Cryptosporidium is a leading cause of pediatric diarrhea in resource-limited settings; yet, few studies report the health care costs or societal impacts of this protozoan parasite. This study examined direct and indirect costs associated with symptomatic cryptosporidiosis in infants younger than 12 months in Kenya, Peru and Bangladesh.

Author: Rafferty E, Schurer J, Arndt M, Choy R, de Hostos E, Shoultz D, Farag M

Publication date: 2017

Region: Global

Host antisecretory targets are a promising treatment option for easing the symptoms of diarrheal disease and addressing shortcomings of existing therapies. This poster presentation from the American Society of Tropical Medicine and Hygiene 2016 Annual Meeting summarizes the results of tests comparing several clinical-stage drug candidates that have the potential to treat acute secretory diarrhea.

Publication date: November 2016

Region: Global

Part of series: ASTMH posters

PATH, in collaboration with the Epidemiology & Disease Control Division, Government of Nepal, and B.P. Koirala Institute of Health Sciences, Dharan, is implementing a focused pharmacovigilance program for kala-azar, or visceral leishmaniasis (VL), in Nepal. The program aims to strengthen patient safety and care associated with the use of VL drugs. The results of the pharmacovigilance activities are summarized in this newsletter.

Publication date: May 2016

Region: Asia

Part of series: Pharmacovigilance newsletters

PATH, in collaboration with the Directorate General Health Services (DGHS), Directorate General Drug Administration (DGDA), Government of Bangladesh (GoB) and International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), is implementing a focused pharmacovigilance program for kala-azar, or visceral leishmaniasis (VL), in Bangladesh. The program aims to strengthen patient safety and care associated with the use of VL drugs. The results of the pharmacovigilance activities are summarized in this newsletter.

Publication date: April 2016

Region: Asia

Part of series: Pharmacovigilance newsletters

This poster presentation from Digestive Disease Week 2014 summarizes the results of a study comparing the pharmacokinetic profiles of a single dose of 300 mg iOWH032 in healthy American volunteers, healthy Bangladeshi volunteers, and Bangladeshi cholera patients with severe diarrhea. In addition, the safety of iOWH032 was assessed in these different populations.

Publication date: April 2014

Region: Global

The cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel offers an attractive target for developing a novel antisecretory to treat infectious diarrhea because it is the primary driver of secretion in cases of diarrhea caused by cholera. iOWH032 is a synthetic CFTR inhibitor that has been studied for this indication.

Author: de Hostos EL, Choy RKM, Nguyen T

Publication date: 2011

Region: Global